Compare POAS & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | POAS | ICCM |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | Singapore | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.6M | 43.4M |
| IPO Year | N/A | 2013 |
| Metric | POAS | ICCM |
|---|---|---|
| Price | $1.69 | $0.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | ★ 1.6M | 136.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $19.87 |
| Revenue Next Year | N/A | $31.38 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.53 | $0.54 |
| 52 Week High | $7.40 | $1.53 |
| Indicator | POAS | ICCM |
|---|---|---|
| Relative Strength Index (RSI) | 41.66 | 58.32 |
| Support Level | $0.53 | $0.58 |
| Resistance Level | $2.27 | $0.74 |
| Average True Range (ATR) | 0.27 | 0.04 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 57.86 | 67.81 |
Phaos Technology Holdings Cayman Ltd is an investment holding company incorporated in the Cayman Islands. Through its subsidiaries, the Company engages in the research, development, manufacturing, and commercialization of advanced optical technologies and products. Leveraging its patented microsphere technology, Phaos enhances the magnification of traditional optical microscopes, enabling visualization beyond the 200nm optical limit at a commercially viable working distance. The Company offers advanced microscopy equipment and parts, along with AI-powered software solutions that complement its hardware to deliver fully integrated microscopy systems. Its technologies serve diverse sectors, including manufacturing, biomedical, and research.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.